In contrast, pharmacological inhibition using PH797804 or knockdown of MAPK14 in colon tumor cells reduces tumor burden in mice.[11] Recent research has demonstrated that MAPK14 is a prognostic biomarker associated with the level of immune infiltration of immune cells, including CD8+ T cells, CD4+ T cells, dendritic cells (DCs), TAMs, etc.[12] In addition, inhibiting p38 MAPK activity with regorafenib represses M2 polarization of macrophages, which suppresses MAPK14‐regulated Creb1 phosphorylation to downregulate Klf4 transcription.[13]. This evidence concerns the gene MAPK14 and colonic neoplasm.